RU2000124084A - Chimeric antibody that binds to human CD40 (variants), nucleic acid molecule (variants), expression vector (variants), humanized antibody (variants), pharmaceutical composition for treating a T-cell mediated disease (variants), method for treating a patient for a disease mediated by T cells (options) - Google Patents

Chimeric antibody that binds to human CD40 (variants), nucleic acid molecule (variants), expression vector (variants), humanized antibody (variants), pharmaceutical composition for treating a T-cell mediated disease (variants), method for treating a patient for a disease mediated by T cells (options)

Info

Publication number
RU2000124084A
RU2000124084A RU2000124084/13A RU2000124084A RU2000124084A RU 2000124084 A RU2000124084 A RU 2000124084A RU 2000124084/13 A RU2000124084/13 A RU 2000124084/13A RU 2000124084 A RU2000124084 A RU 2000124084A RU 2000124084 A RU2000124084 A RU 2000124084A
Authority
RU
Russia
Prior art keywords
variable region
variants
seq
heavy chain
sequence
Prior art date
Application number
RU2000124084/13A
Other languages
Russian (ru)
Other versions
RU2220980C2 (en
Inventor
Алехандро А. АРАФФО
Диан ХОЛЛЕНБОГ
Энтони В. СИАДЭК
Карен К. БЕРРИ
Линда Дж. ХАРРИС
Барбара А. ТОРН
Юрген БАЖОРАТ
Уильям Д. ХЬЮЗ
Херрен ВУ
Джефри Д. УОТКИНС
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/026,291 external-priority patent/US6051228A/en
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of RU2000124084A publication Critical patent/RU2000124084A/en
Application granted granted Critical
Publication of RU2220980C2 publication Critical patent/RU2220980C2/en

Links

Claims (30)

1. Вариабельный участок легкой цепи, содержащий полную аминокислотную последовательность SEQ ID NO:l (Фиг. 4а), или его биологически активный фрагмент.1. The variable region of the light chain containing the complete amino acid sequence of SEQ ID NO: l (Fig. 4A), or a biologically active fragment thereof. 2. Вариабельный участок тяжелой цепи, содержащий полную аминокислотную последовательность SEQ ID NO:2 (Фиг. 4b), или его биологически активный фрагмент.2. The variable region of the heavy chain containing the complete amino acid sequence of SEQ ID NO: 2 (Fig. 4b), or a biologically active fragment thereof. 3. Химерное антитело, которое связывается с CD40 человека, содержащее легкую и тяжелую цепь, причем указанная легкая цепь содержит вариабельный участок по п. 1.3. A chimeric antibody that binds to human CD40 containing a light and heavy chain, said light chain comprising a variable region according to claim 1. 4. Химерное антитело, которое связывается с CD40 человека, содержащее легкую и тяжелую цепь, причем указанная тяжелая цепь содержит вариабельный участок по п. 2.4. A chimeric antibody that binds to human CD40 containing a light and a heavy chain, said heavy chain comprising a variable region according to claim 2. 5. Химерное антитело по п. 3, отличающееся тем, что указанная тяжелая цепь содержит вариабельный участок по п. 2.5. Chimeric antibody according to claim 3, characterized in that said heavy chain contains a variable region according to claim 2. 6. Химерное антитело, которое связывается с CD40 человека, содержащее легкую и тяжелую цепь, причем указанная легкая цепь содержит полную аминокислотную последовательность SEQ ID NO:4 или ее биологически активный фрагмент, а указанная тяжелая цепь содержит полную аминокислотную последовательность SEQ ID NO:3 или ее биологически активный фрагмент.6. A chimeric antibody that binds to human CD40 containing a light and heavy chain, said light chain containing the complete amino acid sequence of SEQ ID NO: 4 or a biologically active fragment thereof, and said heavy chain containing the complete amino acid sequence of SEQ ID NO: 3 or its biologically active fragment. 7. Молекула нуклеиновой кислоты, представляющая собой нуклеотидную последовательность, кодирующую вариабельный участок легкой цепи по п. 1.7. A nucleic acid molecule, which is a nucleotide sequence encoding a variable region of the light chain according to claim 1. 8. Молекула нуклеиновой кислоты, представляющая собой нуклеотидную последовательность, кодирующую вариабельный участок тяжелой цепи по п. 2.8. The nucleic acid molecule, which is a nucleotide sequence encoding the variable region of the heavy chain according to claim 2. 9. Вектор экспрессии, содержащий последовательность нуклеиновой кислоты по п. 7.9. An expression vector containing the nucleic acid sequence of claim 7. 10. Вектор экспрессии, содержащий последовательность нуклеиновой кислоты по п. 8.10. An expression vector containing the nucleic acid sequence of claim 8. 11. Гуманизированное антитело, содержащее фрагмент вариабельного участка легкой цепи по п. 1.11. Humanitariannet antibody containing a fragment of the variable region of the light chain according to claim 1. 12. Гуманизированное антитело, содержащее фрагмент вариабельного участка тяжелой цепи по п. 2.12. Humanitariannet antibody containing a fragment of the variable region of the heavy chain according to claim 2. 13. Фармацевтическая композиция, содержащая химерное антитело по п. 5.13. A pharmaceutical composition comprising a chimeric antibody according to claim 5. 14. Фармацевтическая композиция, содержащая химерное антитело по п. 6.14. A pharmaceutical composition comprising a chimeric antibody according to claim 6. 15. Химерное антитело, которое связывается с CD40 человека, содержащее вариабельный участок легкой цепи и вариабельный участок тяжелой цепи, причем указанный вариабельный участок легкой цепи имеет аминокислотную последовательность, по крайней мере, на 90% идентичную последовательности вариабельного участка легкой цепи по п. 1.15. A chimeric antibody that binds to human CD40 comprising a light chain variable region and a heavy chain variable region, wherein said light chain variable region has an amino acid sequence that is at least 90% identical to the sequence of the light chain variable region of claim 1. 16. Химерное антитело, которое связывается с CD40 человека, содержащее вариабельный участок легкой цепи и вариабельный участок тяжелой цепи, причем указанный вариабельный участок тяжелой цепи имеет аминокислотную последовательность, по крайней мере, на 90% идентичную последовательности вариабельного участка тяжелой цепи по п. 2.16. A chimeric antibody that binds to human CD40 comprising a light chain variable region and a heavy chain variable region, said variable heavy chain region having an amino acid sequence that is at least 90% identical to the sequence of the variable region of the heavy chain according to claim 2. 17. Способ лечения больного, страдающего от заболевания, опосредованного Т-клетками, предусматривающий введение указанному больному терапевтически эффективной дозы фармацевтической композиции по п. 14.17. A method of treating a patient suffering from a T-cell mediated disease, comprising administering to said patient a therapeutically effective dose of a pharmaceutical composition according to claim 14. 18. Молекула нуклеиновой кислоты по п. 7, имеющая последовательность нуклеотидов SEQ ID NO:6.18. The nucleic acid molecule according to claim 7, having the nucleotide sequence of SEQ ID NO: 6. 19. Молекула нуклеиновой кислоты по п. 8, имеющая последовательность нуклеотидов SEQ ID NO:5.19. The nucleic acid molecule according to claim 8, having the nucleotide sequence of SEQ ID NO: 5. 20. Химерное антитело по п. 6, содержащее легкую цепь с аминокислотной последовательностью SEQ ID NO:4 и тяжелую цепь с аминокислотной последовательностью SEQ ID NO:3.20. The chimeric antibody according to claim 6, containing a light chain with the amino acid sequence of SEQ ID NO: 4 and a heavy chain with the amino acid sequence of SEQ ID NO: 3. 21. Гуманизированное антитело по п. 11, содержащее вариабельный участок легкой цепи с последовательностью SEQ ID NO:8.21. The humanized antibody according to claim 11, containing the variable region of the light chain with the sequence of SEQ ID NO: 8. 22. Гуманизированное антитело по п. 11, содержащее вариабельный участок тяжелой цепи с последовательностью SEQ ID NO:10.22. The humanized antibody according to claim 11, containing the variable region of the heavy chain with the sequence of SEQ ID NO: 10. 23. Гуманизированное антитело по п. 12, содержащее вариабельный участок легкой цепи с последовательностью SEQ ID NO:8.23. The humanized antibody according to claim 12, containing the variable region of the light chain with the sequence of SEQ ID NO: 8. 24. Гуманизированное антитело по п. 12, содержащее вариабельный участок тяжелой цепи с последовательностью SEQ ID NO:10.24. The humanized antibody according to claim 12, containing the variable region of the heavy chain with the sequence of SEQ ID NO: 10. 25. Гуманизированное антитело по п. 11, содержащее вариабельный участок легкой цепи с последовательностью SEQ ID NO:8 и вариабельный участок тяжелой цепи с последовательностью SEQ ID NO:10.25. The humanized antibody of claim 11, comprising the variable region of the light chain with the sequence of SEQ ID NO: 8 and the variable region of the heavy chain with the sequence of SEQ ID NO: 10. 26. Гуманизированное антитело по п. 11, содержащее вариабельный участок легкой цепи с последовательностью SEQ ID NO:12.26. The humanized antibody of claim 11, comprising the variable region of the light chain with the sequence of SEQ ID NO: 12. 27. Гуманизированное антитело по п. 26, содержащее вариабельный участок тяжелой цепи с последовательностью SEQ ID NO:10.27. The humanized antibody of claim 26, comprising the variable region of the heavy chain with the sequence of SEQ ID NO: 10. 28. Гуманизированное антитело по п. 11, содержащее вариабельный участок легкой цепи с последовательностью SEQ ID NO:12 и вариабельный участок тяжелой цепи с последовательностью SEQ ID NO:10.28. The humanized antibody of claim 11, comprising the variable region of the light chain with the sequence of SEQ ID NO: 12 and the variable region of the heavy chain with the sequence of SEQ ID NO: 10. 29. Фармацевтическая композиция, содержащая гуманизированное антитело по п. 25.29. A pharmaceutical composition comprising the humanized antibody of claim 25. 30. Фармацевтическая композиция, содержащая гуманизированное антитело по п.28.30. A pharmaceutical composition comprising the humanized antibody of claim 28.
RU2000124084/13A 1998-02-19 1999-02-10 Chimeric antibody that binds with human cd40 (variants), nucleic acid molecule (variants), expression vector (variants), humanized antibody (variants), pharmaceutical composition for treatment of disease mediated by t-cells (variants), method for treatment of patient with diseases mediated by t-cells (variants) RU2220980C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/026,291 US6051228A (en) 1998-02-19 1998-02-19 Antibodies against human CD40
US09/026,291 1998-02-19

Publications (2)

Publication Number Publication Date
RU2000124084A true RU2000124084A (en) 2003-11-10
RU2220980C2 RU2220980C2 (en) 2004-01-10

Family

ID=21830976

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000124084/13A RU2220980C2 (en) 1998-02-19 1999-02-10 Chimeric antibody that binds with human cd40 (variants), nucleic acid molecule (variants), expression vector (variants), humanized antibody (variants), pharmaceutical composition for treatment of disease mediated by t-cells (variants), method for treatment of patient with diseases mediated by t-cells (variants)

Country Status (31)

Country Link
US (3) US6051228A (en)
EP (1) EP1054692A4 (en)
JP (1) JP2002503495A (en)
KR (1) KR100564376B1 (en)
CN (1) CN1198647C (en)
AR (1) AR018101A1 (en)
AU (1) AU751064B2 (en)
BG (1) BG65010B1 (en)
BR (1) BR9908045A (en)
CA (1) CA2321165A1 (en)
CO (1) CO4830493A1 (en)
CZ (1) CZ20003008A3 (en)
EE (1) EE200000470A (en)
GE (1) GEP20033016B (en)
HU (1) HUP0100763A3 (en)
ID (1) ID25792A (en)
IL (2) IL137294A0 (en)
LT (1) LT4837B (en)
LV (1) LV12561B (en)
MY (1) MY121464A (en)
NO (1) NO20004133L (en)
NZ (1) NZ505696A (en)
PE (1) PE20000268A1 (en)
PL (1) PL197143B1 (en)
RU (1) RU2220980C2 (en)
SK (1) SK12092000A3 (en)
TR (1) TR200002405T2 (en)
TW (1) TWI226334B (en)
UA (1) UA71909C2 (en)
WO (1) WO1999042075A2 (en)
ZA (1) ZA991307B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288251B2 (en) 2001-11-09 2007-10-30 Abgenix, Inc. Antibodies to CD40

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US7175847B1 (en) * 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US7153508B2 (en) * 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
JP4219985B2 (en) * 1996-07-23 2009-02-04 タノックス ファーマ ベスローテン フェンノートシャップ Induction of T cell tolerance using soluble molecules capable of simultaneously blocking two costimulatory pathways
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
EP2039368A3 (en) 1999-04-30 2009-04-01 La Jolla Institute For Allergy And Immunology Methods for preventing reactivation of latent virus and controlling virus replication
EP1642596A3 (en) * 1999-05-07 2006-04-12 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US8383081B2 (en) * 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) * 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
AU782160B2 (en) * 1999-06-09 2005-07-07 Immunomedics Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
WO2001013945A1 (en) * 1999-08-23 2001-03-01 Biocrystal Ltd. Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
EP1839674A1 (en) * 1999-10-04 2007-10-03 Novartis Vaccines and Diagnostics, Inc. CD40 antagonist for treating psoriasis
EP1221973B1 (en) * 1999-10-04 2007-05-30 Novartis Vaccines and Diagnostics, Inc. CD40 antagonist for treating psoriasis
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
WO2001034649A2 (en) * 1999-11-09 2001-05-17 Chiron Corporation Compositions and methods for treating autoimmune diseases and transplant rejections
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
GB0006398D0 (en) * 2000-03-16 2000-05-03 Novartis Ag Organic compounds
AU2001259106A1 (en) * 2000-04-19 2002-02-18 Tanox, Inc. CD40 antagonists for use in treating psoriasis and other inflammatory skin conditions
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
MXPA03002262A (en) * 2000-09-18 2003-10-15 Idec Pharma Corp Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination.
AU2002250352C1 (en) * 2001-04-02 2009-04-30 Genentech, Inc. Combination therapy
CN101508734A (en) * 2001-04-27 2009-08-19 协和发酵麒麟株式会社 Anti-CD40 monoclonal antibody
JP4360906B2 (en) * 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー In vivo activation of antigen-presenting cells to enhance the immune response induced by virus-like particles
CA2466931A1 (en) * 2001-11-26 2003-06-05 Chiron Corporation Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
ATE477276T1 (en) * 2002-03-01 2010-08-15 Immunomedics Inc INTERNALIZATION OF ANTI CD74 MONOCLONAL ANTIBODIES AND THEIR USES
US20040175381A1 (en) * 2002-12-09 2004-09-09 Tolerrx, Inc. Inducing tolerance in primates
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
ATE476448T1 (en) * 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic USE OF ANTAGONIST ANTI-CD40 ANTIBODIES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND INFLAMMATORY DISEASES AND ORGAN TRANSPLANT REJECTION
US7674884B2 (en) * 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
KR20060132006A (en) 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. Receptor coupling agents and therapeutic uses thereof
US20090202986A1 (en) * 2004-10-22 2009-08-13 Huse William D Methods of optimizing antibody variable region binding affinity
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
AU2006231622B2 (en) * 2005-04-06 2012-07-05 Bristol-Myers Squibb Company Methods for treating immune disorders associated with graft transplantation with soluble CTLA4 mutant molecules
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
ES2429564T3 (en) * 2005-05-18 2013-11-15 Novartis Ag Procedures for the diagnosis and treatment of diseases that have an autoimmune and / or inflammatory component
DE602006017690D1 (en) 2005-05-26 2010-12-02 Genentech Inc HUMANIZED ANTIBODIES TO CD40 AND METHOD FOR THEIR USE
US7668387B2 (en) * 2005-06-20 2010-02-23 Intel Corporation Selective local transient improvement and peaking for video sharpness enhancement
SI2298815T1 (en) 2005-07-25 2015-08-31 Emergent Product Development Seattle, Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
WO2007033369A2 (en) * 2005-09-14 2007-03-22 University Of Pittsburgh Assessing risk of cerebrovascular thrombosis by measuring c4d on platelets
US20070202549A1 (en) * 2005-09-14 2007-08-30 University Of Pittsburgh Assessing risk of cerebrovascular thrombosis by measuring C4d on platelets
US20080131914A1 (en) * 2005-09-14 2008-06-05 Ahearn Joseph M Assessing risk of cerebrovascular thrombosis by measuring c4d
ES2400660T3 (en) 2005-11-01 2013-04-11 Novartis Ag Uses of anti-CD40 antibodies
EA018301B1 (en) 2006-04-21 2013-07-30 Новартис Аг Pharmaceutical compositions comprising antagonist monoclonal anti-cd40 antibody and use thereof
WO2007130493A2 (en) * 2006-05-03 2007-11-15 Regents Of The University Of Colorado Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
EP1854810A1 (en) * 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
EP2647712A3 (en) * 2006-08-04 2013-11-20 Baxter International Inc Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
ES2381788T3 (en) 2007-07-16 2012-05-31 Genentech, Inc. Anti-CD79b and immunoconjugate antibodies and methods of use
SG183044A1 (en) 2007-07-16 2012-08-30 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugatesand methods of use
UA106586C2 (en) 2008-01-31 2014-09-25 Дженентек, Інк. Anti-cd79b antibodies and imunokonugate and methods for their use
CN105884903B (en) * 2009-03-10 2019-12-06 贝勒研究院 Antigen presenting cell targeted vaccines
ES2618864T3 (en) 2009-03-10 2017-06-22 Baylor Research Institute Vaccines targeting antigen presenting cells
EP2523680A4 (en) * 2010-01-11 2013-06-19 Ct Molecular Med & Immunology Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
DK2796467T3 (en) 2010-03-31 2018-05-07 Boehringer Ingelheim Int Anti-CD40 antibodies
EP3789038B1 (en) * 2010-05-14 2022-10-05 The Board of Trustees of the Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd47
AR083847A1 (en) 2010-11-15 2013-03-27 Novartis Ag FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES
AU2012229236B2 (en) 2011-03-11 2017-05-18 Beth Israel Deaconess Medical Center, Inc. Anti-CD40 antibodies and uses thereof
TWI598363B (en) 2011-04-21 2017-09-11 必治妥美雅史谷比公司 Antibody polypeptides that antagonize cd40
MX339239B (en) 2011-04-29 2016-05-18 Apexigen Inc Anti-cd40 antibodies and methods of use.
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
JP6163158B2 (en) 2011-10-13 2017-07-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Antibody polypeptides that antagonize CD40L
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
WO2013085893A1 (en) 2011-12-05 2013-06-13 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
CN104918957B (en) 2012-10-30 2018-11-16 埃派斯进有限公司 Anti-CD 40 antibodies and its application method
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
CA2884313C (en) 2012-12-13 2023-01-03 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
JP7037884B2 (en) 2014-01-13 2022-03-17 ベイラー リサーチ インスティテュート New vaccines for HPV and HPV-related diseases
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
EP3113796A1 (en) 2014-03-07 2017-01-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
DK3180087T3 (en) 2014-08-12 2019-05-13 Alligator Bioscience Ab COMBINATION THERAPIES WITH ANTI CD40 ANTIBODIES
AU2014406462A1 (en) * 2014-09-16 2017-04-06 Ubi Ip Holdings Treatment and functional cure of HIV infection by monoclonal antibodies to CD4 mediating competitive HIV entry inhibition
EP3689910A3 (en) 2014-09-23 2020-12-02 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
SI3212230T1 (en) 2014-10-29 2021-08-31 Seagen Inc. Dosage and administration of non-fucosylated anti-cd40 antibodies
JP6830437B2 (en) 2014-12-10 2021-02-17 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Genetically modified cells, tissues and organs to treat the disease
CN107428837A (en) 2015-04-22 2017-12-01 免疫医疗公司 Circulate separation, detection, diagnosis and/or the identification of the positive cancer cells of TROP 2
PE20180193A1 (en) * 2015-05-29 2018-01-26 Abbvie Inc ANTI-CD40 ANTIBODIES AND THEIR USES
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
EP3906943A1 (en) 2015-09-04 2021-11-10 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
BR112018006360A2 (en) 2015-09-30 2018-10-09 Janssen Biotech Inc agonistic antibodies that specifically bind to human cd40 and methods of use
US20170224837A1 (en) 2016-02-10 2017-08-10 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
WO2017156349A1 (en) 2016-03-10 2017-09-14 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
EP3448260A4 (en) 2016-04-27 2019-10-09 Immunomedics, Inc. Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
TWI784957B (en) 2016-06-20 2022-12-01 英商克馬伯有限公司 Immunocytokines
US10918734B2 (en) 2017-03-27 2021-02-16 Immunomedics, Inc. Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
US10799597B2 (en) 2017-04-03 2020-10-13 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
SG11202100510PA (en) * 2018-07-20 2021-02-25 Eucure Beijing Biopharma Co Ltd Anti-cd40 antibodies and uses thereof
US20200190163A1 (en) * 2018-10-26 2020-06-18 Lijun Wu Humanized bcma-car-t cells
CN113166246A (en) * 2018-12-28 2021-07-23 四川科伦博泰生物医药股份有限公司 Antibody and application thereof
CN111454362B (en) * 2019-03-04 2021-03-02 北京天广实生物技术股份有限公司 Antibodies that specifically bind to CD40 and uses thereof
US20220348650A1 (en) * 2019-09-03 2022-11-03 Bio-Thera Solutions, Ltd. Anti-tigit immunosuppressant and application thereof
CN113563473A (en) 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 Tetravalent bispecific antibody, preparation method and application thereof
CN111763259B (en) * 2020-09-03 2020-12-15 北京百奥赛图基因生物技术有限公司 anti-CD 40 antibodies and uses thereof
WO2023025248A1 (en) 2021-08-26 2023-03-02 映恩生物制药（苏州）有限公司 Steroid compound and conjugate thereof
WO2023044048A1 (en) * 2021-09-17 2023-03-23 Novartis Ag Methods for prevention of graft rejection in xenotransplantation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU3226593A (en) * 1991-11-26 1993-06-28 Regents Of The University Of California, The Cloning vectors for expressing pcr generated variable regions as complete heavy and/or light chain(s)
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
ATE226641T1 (en) * 1995-04-08 2002-11-15 Lg Chemical Ltd HUMAN 4-1BB SPECIFIC HUMAN ANTIBODIES AND CELL LINE PRODUCING THEM
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
KR20000034847A (en) * 1998-11-17 2000-06-26 성재갑 Humanized Antibody Specific for Human 4-1BB Molecule and Pharmaceutical Composition Comprising Same

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288251B2 (en) 2001-11-09 2007-10-30 Abgenix, Inc. Antibodies to CD40
US7338660B2 (en) 2001-11-09 2008-03-04 Abgenix, Inc. Methods of treating cancer and enhancing immune responses with antibodies that bind CD40
US7563442B2 (en) 2001-11-09 2009-07-21 Abgenix, Inc. Antibodies to CD40 and methods of treating cancer and enhancing immune responses
US7618633B2 (en) 2001-11-09 2009-11-17 Amgen Fremont Inc. Antibodies that bind CD40 and methods of treating cancer and enhancing immune responses
US7626012B2 (en) 2001-11-09 2009-12-01 Amgen Fremont Inc. Nucleic acid molecules which encode antibodies that bind CD40
US8388971B2 (en) 2001-11-09 2013-03-05 Amgen Fremont Inc. Antibodies that bind CD40 and methods of treating cancer and enhancing immune responses

Similar Documents

Publication Publication Date Title
RU2000124084A (en) Chimeric antibody that binds to human CD40 (variants), nucleic acid molecule (variants), expression vector (variants), humanized antibody (variants), pharmaceutical composition for treating a T-cell mediated disease (variants), method for treating a patient for a disease mediated by T cells (options)
RU2220980C2 (en) Chimeric antibody that binds with human cd40 (variants), nucleic acid molecule (variants), expression vector (variants), humanized antibody (variants), pharmaceutical composition for treatment of disease mediated by t-cells (variants), method for treatment of patient with diseases mediated by t-cells (variants)
RU2207878C2 (en) "humanized" antibodies raised against human gp39, compositions comprising these antibodies and their therapeutic using
RU2421464C2 (en) Human il-13 antibodies and their therapeutic application
KR920002315B1 (en) Polypeptides complementary to peptides or proteins having an amino acid sequence or nucleolide coding sequence at least partially known and methods of design therefor
NO20074516L (en) Mammalian cytokine-like polypeptide-1
RU2006115835A (en) HUMAN ANTIBODIES AGAINST HUMAN 4-1BB (CD137)
RU2009103533A (en) METHODS FOR PRODUCING POLYCLONAL ANTIBODIES, ANTI-SERUM CONTAINING POLYCLONAL ANTIBODIES, AND METHODS OF IMMUNIZATION
RU2000109255A (en) "HUMANIZED" ANTIBODIES AGAINST HUMAN GP39, COMPOSITIONS CONTAINING THESE ANTIBODIES AND THEIR THERAPEUTIC USES
HK1154604A1 (en) Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system igm
CA2189015A1 (en) Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases
RU94045919A (en) Antibodies, cells, polypeptide, dna, vectors, method of polypeptide preparing, method of antibody preparing, pharmaceutical composition
RU2009149294A (en) ANTIGEN BINDING PROTEINS AIMED AT ORF0657N S.AUREUS
EA200901129A1 (en) NUCLEIC ACIDS AND POLYPEPTIDES OF THE NEW RECEPTOR
RU98120519A (en) AUTOANTIGEN AND STRUCTURAL-RELATED PROTEINS FOR USE IN IMMUNOTHERAPY OF AUTOIMMUNE DISEASES
RU97105374A (en) MODIFIED PROTEINS
RU2001132140A (en) Recombinant platelet collagen receptor glycoprotein VI and its use in pharmaceuticals
JP2009524428A5 (en)
CA2370098A1 (en) Human beta-trcp protein
ATE310828T1 (en) IMPLANT AND VECTOR FOR THE TREATMENT OF ACQUIRED DISEASES
RU2003129163A (en) POLINUCLEOTID, WHICH CAN BE USED TO MODULATE CANCER CELL PROLIFERATION
WO2004110355A3 (en) Compositions and methods including a recombinant human mab that promotes cns remyelination
JP4310498B2 (en) Human IgM antibody that induces apoptosis in HIV-infected cells and therapeutic agent for HIV infection
RU2002128746A (en) TARGET DELIVERY CONNECTIONS
Dierich Introduction to the Symposium on Complement